Manish Khanolkar

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes

S. J. Creely, Philip G. McTernan, Christine M. Kusminski et al. · American Journal of Physiology-Endocrinology and Metabolism · 2006 · 1K citations

Life Sciences, Endocrinology, Immunology +17

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Effectiveness of text message based, diabetes self management support programme (SMS4BG): two arm, parallel randomised controlled trial

Rosie Dobson, Robyn Whittaker, Yannan Jiang et al. · BMJ · 2018 · 171 citations · Full text

Medicine, Health Behavior, Health Promotion +15

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation

Manish Khanolkar, R.H. Morris, Andrew W. Thomas et al. · Atherosclerosis · 2007 · 46 citations

Medicine, Hematology, Pharmacology +14